



the **Hydroponics** company

www.thcl.com.au

ASX RELEASE (9th January 2018)

\$3m Share Purchase Plan closes

Share Purchase Plan Closed

The Hydroponics Company Limited (ASX:THC) (“**THC**” or “the **Company**”) advises that the 2017 Share Purchase Plan is heavily oversubscribed and has now been closed for further applications. Applications submitted on the 8th January will be accepted into the SPP. No further funds and applications will be accepted after this date.

Due to the significant volume of subscriptions received yesterday any share allocation may be subject to a Board approved scale back.

A shareholder market update will be provided next week.

The original timetable for the issue and allotment of SPP securities will otherwise remain in place.

The Board of Directors thanks the shareholders for their continued support and looks forward to the further growth and development of the THC business model.



The Hydroponics Company Limited
(ASX: THC) ACN: 614 508 039

Suite 305, Level 3
35 Lime Street
Sydney NSW 2000

For further information, please contact:



Jarrod White
Company Secretary | Chief Financial Officer
The Hydroponics Company Limited

Suite 305, Level 3, 35 Lime Street
Sydney NSW 2000

P: +61 2 9251 7177



Michael Lovesey
Director Corporate Media Relations
MMR Corporate Services Pty Ltd

Level 2, 131 Macquarie Street
Sydney, NSW 2000 Australia

P: +61 2 9251 7177

M: +61 449 607 636

E: michaell@mmlrcorporate.com

About The Hydroponics Company

The Hydroponics Company (ASX: THC) is at the forefront of developing a leading, diversified worldwide cannabis business, focused on three core business units: Development and delivery of medicinal cannabis, manufacturing and distribution of hydroponics equipment, materials and nutrients, and large scale hydroponic greenhouse design and construction. With +17 years of Cannabis sativa breeding, variety selection and growth management, THC is actively developing plant breeding technology to target multiple markets for high purity cannabidiol (CBD), a new class of medicinal product that can be used to target dementia, epilepsy and other neurological disorders.